D-Wave Quantum falls nearly 3% as earnings miss overshadows revenue beat
Investing.com - Mizuho has initiated coverage on MBX Biosciences Inc (NASDAQ:MBX) with an Outperform rating and a $38.00 price target, representing significant upside from the current price of $12.54. According to InvestingPro data, analyst targets range from $30 to $44, with the stock currently rated as fairly valued.
The investment firm cites the company’s lead asset canvuparatide (MBX 2109) as having approximately $3.0 billion best-in-class global peak potential in the parathyroid hormone replacement market for hypoparathyroidism. While the company holds more cash than debt and maintains strong liquidity with a current ratio of 23.31, InvestingPro analysis indicates rapid cash burn requires monitoring.
Mizuho’s model incorporates about $1.5 billion in risk-adjusted sales for canvuparatide, highlighting its differentiating weekly dosing schedule that requires approximately 85% fewer injections per year compared to Yorvipath’s daily dosing regimen.
The next major catalyst for canvuparatide will be its Phase 2 readout expected in the third quarter of 2025, which Mizuho believes has a high likelihood of success.
MBX Biosciences also has two other promising long-acting assets in its pipeline: imapextide, a GLP1R antagonist for post-bariatric surgery scheduled to begin Phase 2 trials in the second half of 2025, and MBX 4291, a GLP-1/GIP co-agonist prodrug for obesity with Phase 1 trials expected to commence in the third quarter of 2025.
In other recent news, MBX Biosciences has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for MBX 4291, a long-acting prodrug aimed at treating obesity. The company plans to start a Phase 1 clinical trial for MBX 4291 in the third quarter of 2025, contingent on FDA approval. JMP Securities has reiterated its Market Outperform rating on MBX Biosciences, maintaining a price target of $38.00, citing the strong U.S. launch of Yorvipath, which has a total addressable market exceeding $15 billion. Additionally, Oppenheimer has also reiterated an Outperform rating and a $38.00 price target for MBX Biosciences, ahead of the company’s upcoming Phase 2 clinical trial results. This comes after Oppenheimer initiated coverage on MBX Biosciences, highlighting the company’s innovative Precision Endocrine Peptide platform. JMP Securities observed increased activity in the hypoparathyroidism treatment space, noting that despite new guidelines, some physicians remain hesitant about prescribing Yorvipath. These developments reflect a cautiously optimistic sentiment among analysts and investors toward MBX Biosciences.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.